## 2-(4-chlorophenyl)-3-methyl-N-(2-thiazolyl)butanamide: A Promising Research Target
**2-(4-chlorophenyl)-3-methyl-N-(2-thiazolyl)butanamide** is a synthetic compound with a complex chemical structure. Its importance lies in its potential as a research tool and drug candidate due to its pharmacological properties.
**Here's a breakdown of its potential significance:**
* **Structure:** The compound contains a butanamide backbone, a 4-chlorophenyl substituent, a 2-thiazolyl group, and a methyl group. This specific arrangement of functional groups contributes to its potential biological activity.
* **Pharmacological Activities:** Research suggests that this compound exhibits:
* **Anti-inflammatory properties:** It might inhibit the production of inflammatory mediators, potentially reducing inflammation in various conditions.
* **Antioxidant activity:** It might scavenge free radicals, protecting cells from oxidative damage.
* **Anti-cancer activity:** Some studies indicate that the compound can inhibit the growth of certain cancer cells, possibly by inducing apoptosis (programmed cell death).
**Research Significance:**
* **Drug Development:** The compound's promising pharmacological activities make it a potential drug candidate for conditions like inflammation, oxidative stress-related disorders, and even cancer. Researchers are actively investigating its efficacy and safety in preclinical studies.
* **Understanding Biological Processes:** This compound can serve as a research tool to understand the mechanisms involved in inflammation, oxidative stress, and cancer cell proliferation. Studying its interactions with biological targets can provide insights into these processes.
* **Development of Novel Therapeutics:** Further research might lead to the development of new drugs based on this compound or its derivatives, potentially providing more effective treatments for various diseases.
**Important Note:**
It's crucial to remember that the research on this specific compound is still ongoing, and its potential as a drug or research tool is not yet fully established. More studies are needed to understand its full pharmacological profile, its safety, and its long-term effects.
**In conclusion, 2-(4-chlorophenyl)-3-methyl-N-(2-thiazolyl)butanamide represents a promising research target with potential applications in drug development and understanding fundamental biological processes. Further research is necessary to fully evaluate its therapeutic potential and contribute to the advancement of medical science.**
ID Source | ID |
---|---|
PubMed CID | 4307629 |
CHEMBL ID | 610463 |
CHEBI ID | 113043 |
SCHEMBL ID | 16369644 |
Synonym |
---|
HMS2644I21 |
ENAMINE_000061 |
OPREA1_875848 |
smr000354300 |
MLS001018069 |
CHEBI:113043 |
HMS1394C17 |
CHEMBL610463 , |
bdbm50305973 |
2-(4-chlorophenyl)-3-methyl-n-(thiazol-2-yl)butanamide |
cid_4307629 |
AKOS001033996 |
2-(4-chlorophenyl)-3-methyl-n-(1,3-thiazol-2-yl)butanamide |
4-cmtb |
gtpl5500 |
AKOS016375538 |
300851-67-6 |
4-chloro-?-(1-methylethyl)-n-2-thiazolylbenzeneacetamide |
SR-01000025543-1 |
sr-01000025543 |
SCHEMBL16369644 |
4-chloro-alpha-(1-methylethyl)-n-2-thiazolylbenzeneacetamide |
4-cmtb, >=98% (hplc) |
Z28173527 |
BS-16905 |
Q27073758 |
EN300-1262807 |
CS-0027973 |
HY-P1125 |
mfcd02666163 |
4-chloro-alpha-(1-methylethyl)-n-2-thiazolyl-benzeneacetamide |
(+/-)-4-cmtb |
Class | Description |
---|---|
acetamides | Compounds with the general formula RNHC(=O)CH3. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
glp-1 receptor, partial | Homo sapiens (human) | Potency | 10.0000 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
TDP1 protein | Homo sapiens (human) | Potency | 20.5962 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Smad3 | Homo sapiens (human) | Potency | 1.9953 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
IDH1 | Homo sapiens (human) | Potency | 9.2000 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 16.3601 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 17.0390 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
Vpr | Human immunodeficiency virus 1 | Potency | 56.2341 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
lamin isoform A-delta10 | Homo sapiens (human) | Potency | 11.2202 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 8.9125 | 3.9811 | 46.7448 | 112.2020 | AID720708 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Free fatty acid receptor 2 | Homo sapiens (human) | IC50 (µMol) | 0.8000 | 0.0090 | 0.4045 | 0.8000 | AID454554 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
streptokinase A precursor | Streptococcus pyogenes M1 GAS | EC50 (µMol) | 85.1935 | 0.0600 | 8.9128 | 130.5170 | AID1902; AID1914 |
Estrogen receptor | Rattus norvegicus (Norway rat) | EC50 (µMol) | 150.0000 | 0.0060 | 22.3670 | 130.5170 | AID1914 |
Estrogen receptor beta | Rattus norvegicus (Norway rat) | EC50 (µMol) | 150.0000 | 0.0060 | 22.3670 | 130.5170 | AID1914 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
G protein-coupled receptor activity | Free fatty acid receptor 2 | Homo sapiens (human) |
protein binding | Free fatty acid receptor 2 | Homo sapiens (human) |
lipid binding | Free fatty acid receptor 2 | Homo sapiens (human) |
guanyl-nucleotide exchange factor activity | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
protein binding | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
cAMP binding | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
protein-macromolecule adaptor activity | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
small GTPase binding | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Free fatty acid receptor 2 | Homo sapiens (human) |
cell projection | Free fatty acid receptor 2 | Homo sapiens (human) |
plasma membrane | Free fatty acid receptor 2 | Homo sapiens (human) |
cytosol | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
plasma membrane | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
membrane | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
hippocampal mossy fiber to CA3 synapse | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
plasma membrane | Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
AID454564 | Agonist activity at human FFA2 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP production relative to acetate | 2010 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2 | The first synthetic agonists of FFA2: Discovery and SAR of phenylacetamides as allosteric modulators. |
AID454554 | Agonist activity at human FFA2 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP production | 2010 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2 | The first synthetic agonists of FFA2: Discovery and SAR of phenylacetamides as allosteric modulators. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 5 (71.43) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.20) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |